deltatrials
Terminated PHASE1 NCT01400451

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma

Sponsor: Bristol-Myers Squibb

Conditions Melanoma
Interventions Ipilimumab (BMS-734016) Vemurafenib
Updated 7 times since 2017 Last updated: Dec 10, 2014 Started: Nov 30, 2011 Primary completion: Apr 30, 2013 Completion: Dec 31, 2013

This PHASE1 trial investigates Melanoma and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Roche-Genentech
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States
  • • Los Angeles, United States
  • • New York, United States